Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M Boland

Showing results (501-510 of 571) with videos related to

Pageof 58
Sort By:
The Lancet. Oncology|July 3, 2019
Regorafenib dose-optimisation in patients with refractory metastatic colorectal cancer (ReDOS): a randomised, multicentre, open-label, phase 2 studyTanios S Bekaii-Saab, Fang-Shu Ou, Daniel H Ahn, et al.
International Journal of Cancer|March 7, 2026
TP53 mutation is associated with improved disease control in patients with advanced RAS wild-type colorectal adenocarcinoma treated with cetuximab and pembrolizumabChristos Fountzilas, Spencer Rosario, Agnieszka K Witkiewicz, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 4, 2019
A Fatty Acid Oxidation-dependent Metabolic Shift Regulates the Adaptation of <i>BRAF</i>-mutated Melanoma to MAPK InhibitorsAndrea Aloia, Daniela Müllhaupt, Christophe D Chabbert, et al.
Biorxiv : the Preprint Server for Biology|December 3, 2025
Buoyant mass reveals distinct T cell states predictive of checkpoint responseJiaquan Yu, Ye Zhang, Sarah M Duquette, et al.
Neuro-Oncology|December 15, 2025
Tumor-Infiltrating Lymphocyte Therapy Generated from Melanoma Brain Metastasis: Proof-of-Concept for CNS-Derived Cellular ImmunotherapyEric P Grewal, Samuel J Steuart, Baolin Liu, et al.
Biorxiv : the Preprint Server for Biology|November 18, 2024
Stratified analysis identifies HIF-2<i>α</i> as a therapeutic target for highly immune-infiltrated melanomasAmy Y Huang, Kelly P Burke, Ryan Porter, et al.
Cancer Research Communications|October 31, 2025
Phase II Clinical Trial and Preclinical Evaluation of a Novel CD47 Blockade Combination in Refractory Microsatellite-Stable Metastatic Colorectal CancerRobert W Lentz, Julie Lang, Todd M Pitts, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 5, 2024
Predicting Recurrence-Free and Overall Survival for Patients With Stage II Melanoma: The MIA CalculatorAlexander H R Varey, Isabel Li, Mary-Ann El Sharouni, et al.
ESMO Open|August 27, 2022
Margetuximab with retifanlimab as first-line therapy in HER2+/PD-L1+ unresectable or metastatic gastroesophageal adenocarcinoma: MAHOGANY cohort AD V T Catenacci, Y-K Kang, H H Yoon, et al.
Theranostics|September 30, 2024
Collagen type I PET/MRI enables evaluation of treatment response in pancreatic cancer in pre-clinical and first-in-human translational studiesShadi A Esfahani, Hua Ma, Shriya Krishna, et al.
Pageof 58

Showing results (501-510 of 571) with videos related to

Sort By:
Pageof 58
The Lancet. Oncology|July 3, 2019
Regorafenib dose-optimisation in patients with refractory metastatic colorectal cancer (ReDOS): a randomised, multicentre, open-label, phase 2 studyTanios S Bekaii-Saab, Fang-Shu Ou, Daniel H Ahn, et al.
International Journal of Cancer|March 7, 2026
TP53 mutation is associated with improved disease control in patients with advanced RAS wild-type colorectal adenocarcinoma treated with cetuximab and pembrolizumabChristos Fountzilas, Spencer Rosario, Agnieszka K Witkiewicz, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 4, 2019
A Fatty Acid Oxidation-dependent Metabolic Shift Regulates the Adaptation of <i>BRAF</i>-mutated Melanoma to MAPK InhibitorsAndrea Aloia, Daniela Müllhaupt, Christophe D Chabbert, et al.
Biorxiv : the Preprint Server for Biology|December 3, 2025
Buoyant mass reveals distinct T cell states predictive of checkpoint responseJiaquan Yu, Ye Zhang, Sarah M Duquette, et al.
Neuro-Oncology|December 15, 2025
Tumor-Infiltrating Lymphocyte Therapy Generated from Melanoma Brain Metastasis: Proof-of-Concept for CNS-Derived Cellular ImmunotherapyEric P Grewal, Samuel J Steuart, Baolin Liu, et al.
Biorxiv : the Preprint Server for Biology|November 18, 2024
Stratified analysis identifies HIF-2<i>α</i> as a therapeutic target for highly immune-infiltrated melanomasAmy Y Huang, Kelly P Burke, Ryan Porter, et al.
Cancer Research Communications|October 31, 2025
Phase II Clinical Trial and Preclinical Evaluation of a Novel CD47 Blockade Combination in Refractory Microsatellite-Stable Metastatic Colorectal CancerRobert W Lentz, Julie Lang, Todd M Pitts, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 5, 2024
Predicting Recurrence-Free and Overall Survival for Patients With Stage II Melanoma: The MIA CalculatorAlexander H R Varey, Isabel Li, Mary-Ann El Sharouni, et al.
ESMO Open|August 27, 2022
Margetuximab with retifanlimab as first-line therapy in HER2+/PD-L1+ unresectable or metastatic gastroesophageal adenocarcinoma: MAHOGANY cohort AD V T Catenacci, Y-K Kang, H H Yoon, et al.
Theranostics|September 30, 2024
Collagen type I PET/MRI enables evaluation of treatment response in pancreatic cancer in pre-clinical and first-in-human translational studiesShadi A Esfahani, Hua Ma, Shriya Krishna, et al.
Pageof 58